A Molecular Signature Response Classifier to Predict Inadequate Response to Tumor Necrosis Factor-α Inhibitors: The NETWORK-004 Prospective Observational Study
Stanley Cohen(Metroplex Clinical Research Center), Viatcheslav R. Akmaev, Susan Dina Ghiassian(Boston Engineering (United States)), Joel M. Kremer(Center for Rheumatology), Mengran Wang(BG Medicine (United States)), Alvin F. Wells(Dermatology Research Center), Johanna B. Withers(BG Medicine (United States)), Zoran Gatalica(Caris Life Sciences (United States)), Dimitrios A. Pappas(NewYork–Presbyterian Hospital), Rajat K. Dhar, Erin Connolly-Strong, Theodore Mellors(BG Medicine (United States)), Sarah Rapisardo, Lixia Zhang(BG Medicine (United States)), Jeffrey R. Curtis, Alif Saleh(BG Medicine (United States)), Alex Jones(BG Medicine (United States))
Cited by 34
Related Papers
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
|Arthritis & Rheumatology|2015|2.8k
2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis
|Arthritis Care & Research|2012|1.8k
A Proteome-Scale Map of the Human Interactome Network
|Cell|2014|1.5k